Lower radiation dose study for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (squamous cell type II or III).
- Your cancer is stage IVa (T4N0-2M0 or T1-4N3M0) by AJCC 8th edition or stage III by AJCC 9th edition.
- You have completed 3 cycles of chemotherapy with a platinum drug plus immunotherapy, and your tumor shrunk (partial or complete response) on imaging and your EBV DNA level is undetectable.
- You are between 18 and 70 years old.
- You have good overall health (ECOG score 0 or 1) and adequate organ function (blood counts, liver, kidney, and clotting).
- You have not had previous treatment for your primary tumor or neck lymph nodes (chemotherapy, immunotherapy, targeted therapy, or surgery except for diagnosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests whether a lower dose of radiation is just as effective as the standard dose for people with early-stage nasopharyngeal cancer, and aims to reduce side effects while keeping the cancer under control.
This trial tests a shorter course of radiation therapy for people with nasopharyngeal cancer, a type of head and neck cancer. The goal is to see if a hypofractionated (fewer, larger doses) approach is safe and effective.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.